Overview Dividends

(WST) West Pharmaceutical - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US9553061055

Stoppers, Seals, Syringe Components, Vials, Self-Injection Devices

Health Care Supplies
Market Cap in USD: 19,559m
IPO / Inception: 1978-01-13
Return 12m vs S&P 500: -28.4%

EPS (Earnings per Share)

EPS (Earnings per Share) of WST over the last years for every Quarter: "2020-12": 1.34, "2021-03": 2.05, "2021-06": 2.46, "2021-09": 2.06, "2021-12": 2.04, "2022-03": 2.3, "2022-06": 2.47, "2022-09": 2.03, "2022-12": 1.77, "2023-03": 1.98, "2023-06": 2.11, "2023-09": 2.16, "2023-12": 1.83, "2024-03": 1.56, "2024-06": 1.52, "2024-09": 1.85, "2024-12": 1.82, "2025-03": 1.45, "2025-06": 1.84, "2025-09": 1.96,
EPS CAGR: -1.06%
EPS Trend: -57.0%
Last SUE: 1.45
Qual. Beats: 3

Revenue

Revenue of WST over the last years for every Quarter: 2020-12: 580.3, 2021-03: 671, 2021-06: 724.1, 2021-09: 706.6, 2021-12: 729, 2022-03: 719.7, 2022-06: 771.6, 2022-09: 686.4, 2022-12: 708.4, 2023-03: 715.9, 2023-06: 754.2, 2023-09: 747.5, 2023-12: 732.1, 2024-03: 695.3, 2024-06: 702, 2024-09: 746.9, 2024-12: 748.5, 2025-03: 698.2, 2025-06: 766.2, 2025-09: 804.3,
Rev. CAGR: 2.66%
Rev. Trend: 31.6%
Last SUE: 0.72
Qual. Beats: 0

Dividends

Dividend Yield 0.31%
Yield on Cost 5y 0.31%
Yield CAGR 5y 5.66%
Payout Consistency 93.0%
Payout Ratio 12.0%
Risk via 5d forecast
Volatility 42.2%
Value at Risk 5%th 47.3%
Relative Tail Risk -31.94%
Reward TTM
Sharpe Ratio -0.07
Alpha -28.10
CAGR/Max DD 0.10
Character TTM
Hurst Exponent 0.537
Beta 0.562
Beta Downside 0.521
Drawdowns 3y
Max DD 53.79%
Mean DD 20.78%
Median DD 19.31%

Description: WST West Pharmaceutical December 19, 2025

West Pharmaceutical Services (WST) designs, manufactures, and sells injectable drug containment and delivery systems worldwide, operating through two segments: Proprietary Products-offering stoppers, seals, syringe components, advanced reconstitution technologies, and integrated packaging services for biologic, generic, and pharma customers; and Contract-Manufactured Products-providing automated assembly of surgical, diagnostic, ophthalmic, and consumer drug-delivery devices for pharma and med-device firms. The company leverages a global sales force, distributors, and contract agents to serve markets across the Americas, Europe, the Middle East, Africa, and Asia-Pacific.

Key recent data points: FY 2023 revenue reached approximately $2.6 billion with an operating margin near 13%, reflecting strong demand for biologics packaging; the injectable device market is projected to grow at a 5-6% CAGR through 2029, driven by an expanding pipeline of biologic therapies and heightened regulatory focus on sterility and safety. Additionally, West’s investment in automation and polymer-based vial technologies (e.g., Crystal Zenith) positions it to capture cost-savings and sustainability trends valued by large pharma customers.

For a deeper dive into WST’s valuation metrics and peer comparison, you might find ValueRay’s analyst toolkit useful.

Piotroski VR‑10 (Strict, 0-10) 6.5

Net Income (491.7m TTM) > 0 and > 6% of Revenue (6% = 181.0m TTM)
FCFTA 0.09 (>2.0%) and ΔFCFTA 0.48pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 39.37% (prev 35.95%; Δ 3.42pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.17 (>3.0%) and CFO 693.8m > Net Income 491.7m (YES >=105%, WARN >=100%)
Net Debt (-325.5m) to EBITDA (772.1m) ratio: -0.42 <= 3.0 (WARN <= 3.5)
Current Ratio 2.87 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (72.7m) change vs 12m ago -0.95% (target <= -2.0% for YES)
Gross Margin 35.59% (prev 35.00%; Δ 0.59pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 77.55% (prev 78.26%; Δ -0.71pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 433.6 (EBITDA TTM 772.1m / Interest Expense TTM 1.40m) >= 6 (WARN >= 3)

Altman Z'' 10.49

(A) 0.29 = (Total Current Assets 1.82b - Total Current Liabilities 635.4m) / Total Assets 4.11b
(B) 1.04 = Retained Earnings (Balance) 4.26b / Total Assets 4.11b
warn (B) unusual magnitude: 1.04 — check mapping/units
(C) 0.16 = EBIT TTM 607.0m / Avg Total Assets 3.89b
(D) 3.96 = Book Value of Equity 4.18b / Total Liabilities 1.05b
Total Rating: 10.49 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 71.71

1. Piotroski 6.50pt
2. FCF Yield 1.97%
3. FCF Margin 12.56%
4. Debt/Equity 0.10
5. Debt/Ebitda -0.42
6. ROIC - WACC (= 8.10)%
7. RoE 17.33%
8. Rev. Trend 31.57%
9. EPS Trend -57.00%

What is the price of WST shares?

As of December 22, 2025, the stock is trading at USD 272.54 with a total of 599,924 shares traded.
Over the past week, the price has changed by +0.25%, over one month by +0.54%, over three months by +8.14% and over the past year by -17.04%.

Is WST a buy, sell or hold?

West Pharmaceutical has received a consensus analysts rating of 4.69. Therefore, it is recommended to buy WST.
  • Strong Buy: 10
  • Buy: 2
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the WST price?

Issuer Target Up/Down from current
Wallstreet Target Price 346.1 27%
Analysts Target Price 346.1 27%
ValueRay Target Price 267.4 -1.9%

WST Fundamental Data Overview December 17, 2025

Market Cap USD = 19.56b (19.56b USD * 1.0 USD.USD)
P/E Trailing = 40.3353
P/E Forward = 35.7143
P/S = 6.4808
P/B = 6.3081
P/EG = 3.3801
Beta = 1.166
Revenue TTM = 3.02b USD
EBIT TTM = 607.0m USD
EBITDA TTM = 772.1m USD
Long Term Debt = 202.7m USD (from longTermDebt, last quarter)
Short Term Debt = 22.9m USD (from shortTermDebt, last quarter)
Debt = 303.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -325.5m USD (from netDebt column, last quarter)
Enterprise Value = 19.23b USD (19.56b + Debt 303.0m - CCE 628.5m)
Interest Coverage Ratio = 433.6 (Ebit TTM 607.0m / Interest Expense TTM 1.40m)
FCF Yield = 1.97% (FCF TTM 379.1m / Enterprise Value 19.23b)
FCF Margin = 12.56% (FCF TTM 379.1m / Revenue TTM 3.02b)
Net Margin = 16.30% (Net Income TTM 491.7m / Revenue TTM 3.02b)
Gross Margin = 35.59% ((Revenue TTM 3.02b - Cost of Revenue TTM 1.94b) / Revenue TTM)
Gross Margin QoQ = 36.49% (prev 35.66%)
Tobins Q-Ratio = 4.68 (Enterprise Value 19.23b / Total Assets 4.11b)
Interest Expense / Debt = 0.03% (Interest Expense 100.0k / Debt 303.0m)
Taxrate = 19.54% (34.0m / 174.0m)
NOPAT = 488.4m (EBIT 607.0m * (1 - 19.54%))
Current Ratio = 2.87 (Total Current Assets 1.82b / Total Current Liabilities 635.4m)
Debt / Equity = 0.10 (Debt 303.0m / totalStockholderEquity, last quarter 3.05b)
Debt / EBITDA = -0.42 (Net Debt -325.5m / EBITDA 772.1m)
Debt / FCF = -0.86 (Net Debt -325.5m / FCF TTM 379.1m)
Total Stockholder Equity = 2.84b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.98% (Net Income 491.7m / Total Assets 4.11b)
RoE = 17.33% (Net Income TTM 491.7m / Total Stockholder Equity 2.84b)
RoCE = 19.97% (EBIT 607.0m / Capital Employed (Equity 2.84b + L.T.Debt 202.7m))
RoIC = 16.07% (NOPAT 488.4m / Invested Capital 3.04b)
WACC = 7.97% (E(19.56b)/V(19.86b) * Re(8.09%) + D(303.0m)/V(19.86b) * Rd(0.03%) * (1-Tc(0.20)))
Discount Rate = 8.09% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.55%
[DCF Debug] Terminal Value 77.62% ; FCFE base≈356.1m ; Y1≈343.9m ; Y5≈340.2m
Fair Price DCF = 83.56 (DCF Value 6.01b / Shares Outstanding 71.9m; 5y FCF grow -4.67% → 3.0% )
EPS Correlation: -57.00 | EPS CAGR: -1.06% | SUE: 1.45 | # QB: 3
Revenue Correlation: 31.57 | Revenue CAGR: 2.66% | SUE: 0.72 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.64 | Chg30d=-0.004 | Revisions Net=+2 | Analysts=10
EPS next Year (2026-12-31): EPS=7.78 | Chg30d=-0.002 | Revisions Net=+10 | Growth EPS=+9.6% | Growth Revenue=+6.4%

Additional Sources for WST Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle